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The SARS-CoV-2 B.1.1.7 variant of concern (VOC) is 
increasing in prevalence across Europe. Accurate esti-
mation of disease severity associated with this VOC 
is critical for pandemic planning. We found increased 
risk of death for VOC compared with non-VOC cases in 
England (hazard ratio: 1.67; 95% confidence interval: 
1.34–2.09; p < 0.0001). Absolute risk of death by 28 
days increased with age and comorbidities. This VOC 
has potential to spread faster with higher mortality 
than the pandemic to date
The severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) variant of concern B.1.1.7 (VOC) was 
first identified in Kent, United Kingdom (UK) in autumn 
2020. Early analysis suggests it is more transmissi-
ble than previously circulating forms (non-VOC) [1]. 
It is now the dominant strain throughout the UK and 
is increasing in prevalence across Europe [2]. Early 
reports of increased mortality have not included data 
on individuals’ comorbidities, and this information is 
needed to facilitate pandemic planning.
Certain PCR assays for SARS-CoV-2 do not amplify one 
of the spike protein gene targets in this VOC. Spike 
gene target failure (SGTF) is therefore a proxy for VOC 
identification, with greater than 95% sensitivity for 
VOC diagnosis during the period from 16 November to 
11 January [3].
Working on behalf of NHS England, we estimate the 
risk of death following confirmation of SARS-CoV-2 
infection in England, comparing infection with VOC 
to non-VOC, after accounting for demographic factors 
and comorbidities. The code and configuration of our 




Data were drawn from the OpenSAFELY electronic 
health records secure research platform, covering 40% 
of England’s population registered with a general prac-
titioner (GP) (see Supplement, part 1). We used linked 
data from GPs, SARS-CoV-2 testing, vaccination and 
mortality records (Supplementary Table S1).
We defined as cases those who tested positive for 
SARS-CoV-2 between 16 November 2020 and 11 January 
2021 and followed them until death or 5 February, 
when follow-up was censored. Vaccinations against 
SARS-CoV-2 and diagnoses before the study period 
were exclusion criteria. The SGTF status was known for 
184,786 of 441,161 (42%) people with confirmed SARS-
CoV-2 infection between 16 November and 11 January 
(91,775 VOC; 93,011 non-VOC) (Supplementary Table 
S4). Full details of the design and analysis are avail-
able in the protocol (Supplement, part 9). A total of 
867 (419 VOC; 448 non-VOC) all-cause deaths occurred 
before the administrative censor on 5 February 2021.
The exposure groups were similar demographically 
(Table 1). The VOC group was younger with a lower pro-
portion of older cases (≥ 80 years: 0.9% in the VOC vs 
1.6% in the non-VOC group), with fewer comorbidities 
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Table 1
Demographic and clinical characteristics of the study population, SARS-CoV-2 B.1.1.7 fatality risk, England, 16 November 
2020–5 February (n =184,786)
Total Non-VOC cases VOC cases
n % n % n %
Total population 184,786 91,775 93,011
Deaths 867 0.5 448 0.5 419 0.5
Time to death (days)
   Median (IQR) 13.0 (9.0–21.0) 13.0 (8.0–22.0) 14.0 (9.0–21.0)
Follow-up time
   Median (IQR) 43.0 (33.0–60.0) 57.0 (40.0–72.0) 36.0 (30.0–45.0)
Epidemiological week of diagnosis
   16 Nov–22 Nov 21,976 11.9 20,854 22.7 1,122 1.2
   23 Nov–29 Nov 14,755 8.0 13,432 14.6 1,323 1.4
   30 Nov–6 Dec 14,286 7.7 11,576 12.6 2,710 2.9
   7 Dec–13 Dec 18,137 9.8 11,703 12.8 6,434 6.9
   14 Dec–20 Dec 19,963 10.8 9,043 9.9 10,920 11.7
   21 Dec–27 Dec 24,422 13.2 8,246 9.0 16,176 17.4
   28 Dec–3 Jan 34,527 18.7 9,477 10.3 25,050 26.9
   4 Jan–11 Jan 36,720 19.9 7,444 8.1 29,276 31.5
Sex
   Female 98,099 53.1 49,468 53.9 48,631 52.3
   Male 86,687 46.9 42,307 46.1 44,380 47.7
Age group (years)
   0– <18 27,228 14.7 14,310 15.6 12,918 13.9
   18– < 30 36,969 20.0 17,302 18.9 19,667 21.1
   30– < 40 34,298 18.6 16,782 18.3 17,516 18.8
   40– < 50 32,783 17.7 15,904 17.3 16,879 18.1
   50– < 60 30,484 16.5 15,261 16.6 15,223 16.4
   60– < 70 14,818 8.0 7,587 8.3 7,231 7.8
   70– < 80 5,860 3.2 3,116 3.4 2,744 3.0
   ≥ 80 2,346 1.3 1,513 1.6 833 0.9
Ethnicity
   White 105,428 57.1 52,687 57.4 52,741 56.7
   South Asian 21,562 11.7 11,880 12.9 9,682 10.4
   Black 4,530 2.5 1,753 1.9 2,777 3.0
   Mixed 2,628 1.4 1,175 1.3 1,453 1.6
   Other 2,974 1.6 1,351 1.5 1,623 1.7
   Missing 47,664 25.8 22,929 25.0 24,735 26.6
Categorical number of comorbiditiesa
   0 158,017 85.5 77,538 84.5 80,479 86.5
   1 20,606 11.2 10,768 11.7 9,838 10.6
   ≥ 2 6,163 3.3 3,469 3.8 2,694 2.9
Index of multiple deprivation quintile
   1 least deprived 36,560 19.8 15,973 17.4 20,587 22.1
   2 34,767 18.8 16,000 17.4 18,767 20.2
   3 35,181 19.0 16,192 17.6 18,989 20.4
   4 38,603 20.9 19,479 21.2 19,124 20.6
   5 most deprived 39,675 21.5 24,131 26.3 15,544 16.7
a Comorbidities as defined in Supplementary Table S2.
A full table including all factors adjusted for is given in Supplementary Table S3.
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Figure 1
Hazard ratios for death following diagnosis of infection with SARS-CoV-2 VOC vs non-VOC, England, 16 November 
2020–5 February (n =184,786)
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HR: hazard ratio; IMD: index of multiple deprivation; NE: North East; SE: South East; UTLA: upper tier local authority; VOC: variant of concern.
*Likelihood ratio test for interaction between exposure group (VOC, non-VOC) and subgroup.
Cox proportional hazards regression; all models are stratified on region by UTLA; estimating a separate baseline hazard function for each UTLA, with model 
parameters estimated by maximum likelihood over the full study population.
The demographically adjusted model includes adjustment for: age, sex, IMD, ethnicity, household size, rural urban classification, epidemiological week and care 
home status. The fully adjusted model includes adjustment for: age, sex, IMD, ethnicity, smoking status, obesity, household size, rural urban classification, 
comorbidities, epidemiological week and care home status. There was no evidence of non-proportional hazards in this model (global test of Schoenfeld 
residuals, p = 0.19). The first sensitivity analysis is restricted to people with a minimum of 28 days from testing positive for SARS-CoV-2 to the follow-up 
censor. The SE and NE NHS England regions are excluded from the second sensitivity analysis (for details see Supplement part 7). The causal minimum 
adjustment set includes adjustment for: age, care home status, comorbidities, IMD and smoking status.
Missing ethnicity data was imputed for the final listed sensitivity analysis. All subgroup analyses were performed on the fully adjusted model.
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(two or more comorbidities: 2.9% vs 3.8%). Non-VOC 
cases were more frequent in the first 4 weeks of the 
study period, while VOC cases predominated thereaf-
ter. Consequently, median follow-up time was shorter 
among the VOC group (36 days; interquartile range 
(IQR): 30–45) than the non-VOC group (57 days; IQR: 
40–72).
Relative hazard of death
We calculated the relative hazard of death for VOC com-
pared with non-VOC cases using a Cox proportional 
hazards regression model stratified by region (upper 
tier local authority area (UTLA)) [4,5]. Follow-up began 
at the date of testing positive for SARS-CoV-2 and was 
censored on 5 February 2021 or 7 days before receipt of 
a SARS-CoV-2 vaccine, whichever came first. The 7 days 
prior to vaccination were censored in this analysis to 
remove a potential immortal time bias because illness 
which may lead to death would exclude the booking of 
and administration of a vaccine. Infection with the VOC 
was consistently associated with an increased hazard 
of death. In a fully adjusted analysis accounting for 
demographics and comorbidities, hazards were two-
thirds higher in the VOC group (hazard ratio (HR): 1.67; 
95% confidence interval (CI): 1.34–2.09; p < 0.0001) 
compared with non-VOC (Figure 1). Increased hazards 
for VOC were consistent across all pre-specified sub-
group analyses including epidemiological week, age 
group, categorical number of comorbidities, ethnicity 
and index of multiple deprivation (IMD) quintile [6]. 
Increased hazards were also consistent across all pre-
specified sensitivity analyses; in an analysis restricted 
to people testing positive for SARS-CoV-2 infection 
a minimum of 28 days before the censoring date, the 
hazard ratio was 1.71 (95% CI: 1.36–2.15; p < 0.0001).
Absolute risk of death by 28 days
We found a consistently higher absolute risk of death by 
28 days after a SARS-CoV-2-positive test in all groups 
stratified by age, sex and presence of comorbidities in 
Table 2
Absolute risk of death by 28 days, SARS-CoV-2 VOC vs non-VOC infection, England, 16 November 2020–5 February 
(n =112,979)
Sex Age group (years)
Non-VOC VOC





0– < 65 0.05 0.03–0.06 0.07 0.06–0.09
65– < 75 0.45 0.30–0.59 0.72 0.50–0.95
75– < 85 1.08 0.71–1.45 1.73 1.15–2.31




0– < 65 0.09 0.07–0.11 0.14 0.11–0.17
65– < 75 0.85 0.59–1.12 1.37 0.96–1.77
75– < 85 2.03 1.35–2.71 3.24 2.19–4.30





0– < 65 0.11 0.08–0.15 0.18 0.13–0.24
65– < 75 1.09 0.78–1.41 1.75 1.25–2.25
75– < 85 2.60 1.84–3.35 4.13 2.94–5.32




0– < 65 0.22 0.15–0.28 0.35 0.25–0.45
65– < 75 2.06 1.51–2.62 3.29 2.44–4.14
75– < 85 4.81 3.48–6.14 7.54 5.52–9.55
≥ 85 9.94 6.87–13.01 15.10 10.63–19.58




0– < 65 0.21 0.14–0.28 0.34 0.22–0.45
65– < 75 1.99 1.41–2.57 3.18 2.27–4.09
75– < 85 4.66 3.45–5.87 7.31 5.42–9.20




0– < 65 0.40 0.27–0.52 0.64 0.44–0.84
65– < 75 3.72 2.74–4.69 5.87 4.38–7.35
75– < 85 8.44 6.44–10.44 12.93 9.99–15.87
≥ 85 16.65 12.42–20.88 24.34 18.55–30.13
Absolute risk is calculated from the marginal means of a fully adjusted logistic regression model with outcome death by 28 days after positive 
test for SARS-CoV-2, restricted to the population with a minimum of 28 days from testing to the follow-up censor. Deaths beyond 28 days 
were censored. The fully adjusted model includes adjustment for: age, sex, index of multiple deprivation, ethnicity, smoking status, 
obesity, household size, NHS England region, rural/urban classification, comorbidities, epidemiological week and care home status.
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VOC, compared with non-VOC (Table 2). Risk of death 
was estimated by the marginal means of a fully adjusted 
logistic regression model. This analysis was restricted 
to 112,979 people diagnosed with SARS-CoV-2 a mini-
mum of 28 days before the censoring date, with the 
outcome death by 28 days after a positive test. Deaths 
occurring beyond 28 days were censored. Data were 
not censored 7 days prior to vaccination in this analysis 
as vaccination is contraindicated in the month follow-
ing a positive SARS-CoV-2 test. Consistent with the Cox 
model above, VOC was associated with increased odds 
of death in this model (adjusted odds ratio (AOR): 1.73; 
95% CI: 1.34–2.23; p value < 0.0001, vs non-VOC). The 
risk of death was low for people younger than 65 years 
in the absence of comorbidities; in this age group it was 
higher for male than female cases (VOC: males: 0.14%; 
females: 0.07% vs non-VOC: males: 0.09%; females: 
0.05%). The risk of death was consistently higher for 
male cases and increased with age and the presence of 
comorbidities. The highest risk of death within 28 days 
was seen among those 85 years and older with two 
or more comorbidities: VOC: males 24.3%; females: 
14.7%; non-VOC: males: 16.7%; females: 9.7%). The 
excess risk of death within 28 days for VOC compared 
with non-VOC is shown in Figure 2.
Discussion
The SARS-CoV-2 B.1.1.7 VOC has been the subject of 
intense research since its emergence. Increased trans-
missibility means it is now the most common variant in 
the UK, a trend confirmed here. We found that this VOC 
was associated with two-thirds higher case fatality than 
the previously circulating virus in this unvaccinated 
population. For every three deaths in a population with 
the previously circulating virus we would expect five 
deaths in a similar population with VOC. Other studies 
have assessed the relative mortality of the VOC with 
similar conclusions [7-10], however, our results are the 
first to include detailed information on the presence 
of comorbidities. Interestingly, the effects of age and 
comorbidities appear to be collinear as adjustment for 
comorbidities did not alter the findings after adjust-
ment for age. As prevalence of many comorbidities is 
associated with age, this finding appears plausible 
[11]. The consistency of the effect for each epidemio-
logical week of diagnosis shows that the increase in 
mortality due to VOC could not be explained by other 
secular changes in mortality such as hospitals exceed-
ing capacity.
The absolute risks of death by 28 days demonstrated 
an increasing risk with age and presence of comor-
bidities; male cases had a consistently higher risk of 
death than female cases. However, age and comorbid-
ity risk factors associated with poor non-VOC outcomes 
appear to be similar to those with this VOC. Therefore, 
prioritisation for vaccination and shielding can remain 
the same.
In the UK, all-cause death by 28 days after confirma-
tion of SARS-CoV-2 infection is the standard definition 
of SARS-CoV-2 mortality [12], so we used death from 
any cause as the primary outcome. In a sensitivity 
analysis restricted to people diagnosed with SARS-
CoV-2, a minimum of 28 days before the censoring date 
and logistic regression with deaths censored beyond 
28 days, the results were consistent.
This analysis includes people testing positive for SARS-
CoV-2. People with asymptomatic or mild infection may 
Figure 2
Excess risk of death by 28 days, SARS-CoV-2 VOC compared with non-VOC infection, England, 16 November 2020–5 
February (n =112,979)
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VOC: variant of concern.
The figure shows risk difference of death by 28 days for VOC compared with non-VOC, with 95% confidence interval.
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not present for testing. Consequently, our estimates of 
absolute risk of death by 28 days may be overestimates 
of the true case fatality ratio. In addition, SARS-CoV-2 
tests performed in hospital settings in the UK are not 
tested for PCR S-gene target failure and are therefore 
not included.
This VOC is now prevalent across Europe and is likely to 
become the most frequent variant following the pattern 
seen in the UK [2]. Policymakers and pandemic plan-
ners need to account for higher mortality of this VOC.
Crucially, emerging data suggest that the currently 
approved vaccines for SARS-CoV-2 are effective against 
the B.1.1.7 VOC [13]. This study highlights the impor-
tance of robust national vaccination programmes and 
infection control measures to contain the SARS-CoV-2 
pandemic. Unmitigated spread of the B.1.1.7 VOC has 
the potential to be both faster and more deadly than 
the pandemic to date.
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